H. pylori Eradication and Type 2 Diabetes Management

Does H. pylori Eradication Affect HbA1c?

person doing an online search for diabetes informationTreatment to eradicate the helicobacter pylori (H. pylori) bacteria has been widely performed. Additionally, type 2 diabetes is becoming more prevalent throughout the world.

Therefore, in a study, Japanese researchers investigated the influence H. pylori eradication treatment has on type 2 diabetes management.

The results of their study appeared online in February 2012 in the article “Influence of helicobacter pylori eradication on the management of type 2 diabetes.” This article will appear in an issue of the journal Hepato-Gastroenterology.

The study included 174 patients who had type 2 diabetes. Study participants did not have an active peptic ulcer or any other serious complication related to H. pylori. In addition, the patients were successfully cured of their H. pylori infection at the researchers’ institute.

Using a paired Student’s t-test, researchers evaluated 2 key values in the participants: mean glycosylated hemoglobin (HbA1c) and body mass index (BMI). They looked at HbA1c and BMI during the year before and the year after H. pylori eradication.

What Researchers Learned about H. pylori Eradication and Type 2 Diabetes Management
The research team did not observe any significant changes to the mean HbA1c values in study participants during the year before or after eradication of H. pylori infection.

But the researchers found that H. pylori eradication significantly increased BMI. BMI didn’t change in the year before eradication, but when compared with the mean BMI at the time point of H. pylori eradication (22.9±2.6 kg/m2), it significantly increased at 6 months after eradication (23.1±2.6 kg/m2; p<0.05). It also increased significantly at 12 months after eradication (23.1±2.7 kg/m2; p<0.05).

At the end of the study, the research team concluded that although eradication of H. pylori significantly increased BMI, it did not affect HbA1c values in patients who have type 2 diabetes; this was observed even though the participants were being treated for type 2 diabetes.

Continue Reading:
FDA Adds New Warning to Labels of Saxagliptin and Alogliptin Products